The BELIEVE trial has shown that a combination of intravenous bimagrumab and subcutaneous semaglutide leads to significant weight loss and fat mass reduction without compromising lean mass. The study, presented at the American Diabetes Association’s 85th Scientific Sessions, involved 507 patients with obesity and demonstrated that the combination therapy resulted in more than 20% weight loss at 72 weeks, with bimagrumab 30 mg/kg and semaglutide 2.4 mg being the most effective.
Full Story: Healio (free registration) (6/23)